Evidence for Vascular Endothelial Growth Factor (VEGF) as a Modifier Gene in Psoriasis

Journal of Investigative Dermatology

Volumn 122, Issue 1, 2004, Pages

  Detmar, Michael ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

AUTOIMMUNE DISEASE; BINDING AFFINITY; BIOACCUMULATION; BLOOD VESSEL PERMEABILITY; CELL DIFFERENTIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA MODIFICATION; DNA POLYMORPHISM; GENE LOCATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; INTRACELLULAR SPACE; NONHUMAN; NOTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PSORIASIS; SCORING SYSTEM; SKIN INFLAMMATION; T LYMPHOCYTE; UPREGULATION;

EID: 1642534521     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-202X.2003.22140.x     Document Type: Note

References (15)

1. Awata T, Inoue K, Kurihara S, et al: A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51:1635-1639, 2002
2. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE: Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141:1054-1060, 1999
3. Braverman IM, Sibley J: Role of the microcirculation in the treatment and pathogenesis of psoriasis. J Invest Dermatol 78:12-17, 1982
4. Creamer D, Allen MH, Groves RW, Barker JN: Circulating vascular permeability factor/vascular endothelial growth factor in erythroderma. Lancet 348:1101, 1996
5. Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R, Barker J: Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138:791-796, 2002
6. Detmar M: The roles of VEGF and thrombospondins in skin angiogenesis. J Dermatol Sci 24 (Suppl 1):S78-S84, 2000
7. Detmar M, Brown LF, Schon MP, et al: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 111:1-6, 1998
8. Detmar M, Brown LF, Claffey KP, et al: Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180:1141-1146, 1994
9. Huez I, Bornes S, Bresson D, Creancier L, Prats H: New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol Endocrinol 15:2197-2210, 2001
10. Lambrechts D, Storkebaum E, Morimoto M, et al: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34:383-394, 2003
11. Nielsen HJ, Christensen IJ, Svendsen MN, et al: Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. Inflamm Res 51:563-567, 2002
12. Trembath RC, Clough RL, Rosbotham JL, et al: Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6:813-820, 1997
13. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor gene: Correlation with variation in VEGF protein production. Cytokine 12:1232-1235, 2000
14. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS: Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102:161-168, 2003
15. Young HS, Summers AM, Bhushan M, Brenchley PEC, Griffiths CEM, Single nucleotide polymorphisms of vascular endothelial growth factor (VEGF) in psoriasis of early onset. J Invest Dermatol 122:209-215, 2004